When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care.

Prof Ana Santos Rutschman talks about the impact of intellectual property regimes on domestic and global responses to the COVID-19 pandemic.

Dr Steven Goodman talks about the ethical and scientific implications of breaking the blind of placebo-controlled COVID-19 vaccine trials.

Dr Arthur Caplan talks about ethical issues surrounding the development, production, and use of potential SARS-CoV-2 vaccine.

Dr Caleb Alexander examines the US Food and Drug Administration's controversial decision to approve aducanumab for the treatment of Alzheimer's Disease.

Drs Stefano Bertozzi and Jeffrey Mackie-Mason talk about business models of scientific publishing that advance biomedical knowledge and discovery.

Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients.

The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient.

Noninvasive prenatal testing arguably constitutes a form of eugenics in a social context in which certain reproductive outcomes are not valued.

A philosophy professor argues that prenatal genetic testing allows potentially painful afflictions to be discovered prior to birth and does not unjustly discriminate against disabled people.